Skip to content
Clinical Trials – home
RomaniaBack to Romania

Clinical trials in Ramnicu Valcea

40 clinical trials in Ramnicu Valcea, Romania. Every trial is listed in the EU Clinical Trials Register and updated daily.

RomaniaOur site in RomaniaStudii.Clinice.ro(opens in a new tab)
Ramnicu Valcea at a glance
40
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

40 trials in Ramnicu Valcea

Open in trial search

Obesity+1

Recruiting

A Phase III Study of Once‑Weekly Petrelintide to Evaluate Efficacy and Safety for Weight Loss in Adults with Overweight or Obesity

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Petrelintide
  • Sponsor:F. Hoffmann-La Roche AG

Cardiac failure

Recruiting

Study of maridebart cafraglutide for patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim Espana S.A.

Cardiac failure

Recruiting

Evaluating the Effect of Vicadrostat and Empagliflozin Combination Compared to Empagliflozin Alone in Patients with Heart Failure and Reduced Left Ventricular Function

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim International GmbH

Cardiac failure

Recruiting

Study on BI 690517 and Empagliflozin for Patients with Heart Failure and Preserved Ejection Fraction

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim International GmbH

Cardiac failure

Recruiting

Study on the Effects of Finerenone in Patients with Heart Failure and Preserved Ejection Fraction Hospitalized for Acute Decompensated Heart Failure

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Finerenone
  • Sponsor:Colorado Prevention Center

Zenagamtide versus semaglutide: a study of blood sugar and weight reduction in adults with type 2 diabetes inadequately controlled on metformin and/or SGLT2 inhibitor

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Novo Nordisk A/S

Study on Ferric Derisomaltose for Patients with Iron Deficiency and Chronic Heart Failure

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Ferric Derisomaltose
  • Sponsor:Pharmacosmos A/S

Still's disease+1

Recruiting

Study on the Effectiveness and Safety of Deucravacitinib for Children and Teens with Juvenile Psoriatic Arthritis

Investigational
Countries:RomaniaRomania
  • Participants:0–17 years
  • Substances:Deucravacitinib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study on the Effectiveness of 2LPAPI with Interferon Alfa in Clearing Genital HPV Infections in Patients

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years
  • Substances:Ciclosporin A
  • Sponsor:Labo'Life Belgium

Atrial fibrillation

Not yet recruiting

Stroke and Systemic Embolism Prevention with REGN7508 and REGN9933 in Adults with Atrial Fibrillation Unsuitable for Oral Anticoagulation (Phase 3)

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:REGN9933
  • Sponsor:Regeneron Pharmaceuticals Inc.

Atrial fibrillation

Not yet recruiting

Prevention of Stroke and Systemic Embolism in Atrial Fibrillation Patients Treated with REGN7508 (cenvacibart) versus Apixaban

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Regeneron Pharmaceuticals Inc.

Other cities in Romania

The busiest research cities in the country

All 63 cities in Romania

Clinical research in Ramnicu Valcea

What the registry says about research in the country

01 Autoimmune Disorders

Innovative research focusing on Systemic Lupus Erythematosus (SLE) treatments, evaluating multiple novel therapeutic compounds including cenerimod and deucravacitinib for reducing disease activity and improving long-term patient outcomes.

  • SLE Management Studies
  • Long-term Safety Evaluations
  • Disease Activity Monitoring

Clinical investigations aim to establish new treatment standards for patients with moderate to severe disease manifestations.

02 Rheumatic Conditions

Comprehensive studies examining treatments for Psoriatic Arthritis and Juvenile Psoriatic Arthritis, including new biological therapies and innovative compounds for both adult and pediatric populations.

  • Adult PsA Treatment Studies
  • Pediatric Arthritis Research
  • Biologic Therapy Evaluation

Research focuses on reducing symptoms and improving quality of life across different age groups.

03 Inflammatory Disorders

Ground-breaking research into Sjögren's Syndrome and dermatomyositis, testing novel therapeutic approaches including sibeprenlimab and ianalumab for symptom management and disease control.

  • Inflammatory Disease Markers
  • Novel Treatment Approaches
  • Symptom Management Studies

Studies aim to advance understanding of inflammatory condition treatments and their long-term effectiveness.

04 Musculoskeletal Conditions

Advanced research examining osteoarthritis and axial spondyloarthritis, including innovative pain management solutions and disease-modifying treatments.

  • Pain Management Protocols
  • Joint Function Studies
  • Treatment Safety Assessments

Investigations focus on improving mobility and reducing pain in chronic musculoskeletal conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.